AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16205336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with and without physical modalities
Number of subjects: 681
Study 16205336 — intervention group
Group type: COMPARATOR
Intervention: Medical care with and without physical therapy
Number of subjects: 681
Study 10600916 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (XO inhibitor)
Number of subjects: 16
Study 10600916 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 16
Study 8545745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxoside (1,200‐3,200 mg standardized Hypoxis plant extract per day divided in 3 doses)
Number of subjects: 24
Study 8545745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxoside
Number of subjects: 24
Study 2322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release capsules of 120 mg administered every 12 h
Number of subjects: 6
Study 2322638 — intervention group
Group type: COMPARATOR
Intervention: Regular 60 mg tablets administered every 6 h
Number of subjects: 6
Study 7437261 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine in patients treated with antiepileptic drugs
Number of subjects: 19
Study 7437261 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐glucaric acid (D‐GA) excretion in patients treated with antiepileptic drugs
Number of subjects: 19
Study 7437261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine in patients treated with antiepileptic drugs
Number of subjects: 19
Study 7437261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine clearance correlation in all subjects
Number of subjects: 19
Study 7437261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine clearance correlation in normal subjects
Number of subjects: 19
Study 7437261 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine clearance correlation in epileptic patients
Number of subjects: 19
Study 31077258 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 1493
Study 31077258 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 20 mg twice daily
Number of subjects: 1493
Study 31077258 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1493
Study 28424063 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPA screening tool for early detection of malnutrition
Number of subjects: 824
Study 28424063 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient clinical care (Control)
Number of subjects: 824
Study 27348402 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing a hyperoxic gas mixture with a constant fraction of 60% inhaled oxygen during exercise training
Number of subjects: 88
Study 27348402 — intervention group
Group type: COMPARATOR
Intervention: Breathing up to 40% oxygen as required to maintain an oxygen saturation level of at least 88% during exercise training (control group)
Number of subjects: 88
Study 27348402 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen delivery during exercise training
Number of subjects: 88
Study 25191864 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 431
Study 25191864 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy
Number of subjects: 431
Study 25191864 — intervention group
Group type: COMPARATOR
Intervention: Ulcer duration, size, and healing time
Number of subjects: 431
Study 22999402 — intervention group
Group type: EXPERIMENTAL
Intervention: Subxiphoid drain (SX group)
Number of subjects: 36
Study 22999402 — intervention group
Group type: COMPARATOR
Intervention: Intercostal drain (IC group)
Number of subjects: 36
Study 19190969 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasoned surgeons
Number of subjects: 12
Study 19190969 — intervention group
Group type: COMPARATOR
Intervention: Control surgeons
Number of subjects: 12
Study 19190969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 17444850 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (40 KD) plus ribavirin 600-1000 mg/day
Number of subjects: 201
Study 17444850 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alpha-2a plus placebo
Number of subjects: 201
Study 17444850 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a plus ribavirin 600-1000 mg/day
Number of subjects: 201
Study 17444850 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alpha-2a monotherapy
Number of subjects: 201
Study 15871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 30 microg/kg
Number of subjects: 30
Study 15871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 60 microg/kg
Number of subjects: 30
Study 15871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microg/kg
Number of subjects: 30
Study 15871195 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 30
Study 11990805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the subthalamic nucleus (STN)
Number of subjects: 12
Study 9811023 — intervention group
Group type: EXPERIMENTAL
Intervention: octyl‐2‐cyanoacrylate
Number of subjects: 111
Study 9811023 — intervention group
Group type: COMPARATOR
Intervention: sutures
Number of subjects: 111
Study 7645926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose medroxyprogesterone acetate (MPA) treatment (600, 800, 1200 mg/day or changed dosage)
Number of subjects: 49
Study 7645926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose medroxyprogesterone acetate (MPA) treatment
Number of subjects: 49
Study 2749132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular immunotherapy for 2 years
Number of subjects: 21
Study 2749132 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for 1 year
Number of subjects: 21
Study 29667870 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-focused interpretations (PF-interpretations)
Number of subjects: 65
Study 29667870 — intervention group
Group type: COMPARATOR
Intervention: Non-panic-focused interpretations (non-PF-interpretations)
Number of subjects: 65
Study 27894777 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting-release octreotide (20 mg intramuscularly, 2 doses, 4 weeks before and on the day of surgery)
Number of subjects: 65
Study 27894777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25165165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant adenovirus serotype 26 HIV-1 vaccine
Number of subjects: 0
Study 24938136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40-60 mg/day for 14 days)
Number of subjects: 92
Study 24938136 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotrophin hormone (40-60 IU every other day for 14 days)
Number of subjects: 92
Study 23016516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 24
Study 19465798 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of extra virgin olive oil for 3 months (group A)
Number of subjects: 34
Study 19465798 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of extra virgin olive oil for 3 months (group B)
Number of subjects: 34
Study 17504254 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental ostial pulmonary vein ablation (Group 1)
Number of subjects: 73
Study 17504254 — intervention group
Group type: COMPARATOR
Intervention: Circumferential ablation with PV-LA block (Group 2)
Number of subjects: 73
Study 15350001 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular adsorbents recirculating system (MARS) therapy over 7 days
Number of subjects: 18
Study 15350001 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 18
Study 15350001 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS therapy
Number of subjects: 18
Study 15350001 — intervention group
Group type: COMPARATOR
Intervention: SMT
Number of subjects: 18
Study 11598598 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified cereal (156 mg/serving)
Number of subjects: 27
Study 11598598 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium cereal (39 mg/serving)
Number of subjects: 27
Study 9726182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 163
Study 7977479 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (CaAC), mean dose 4.1 +/- 0.3 g/day
Number of subjects: 10
Study 7977479 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3), mean dose 4.01 +/- 0.8 g/day
Number of subjects: 10
Study 2658526 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg)
Number of subjects: 10
Study 2658526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4611579 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg daily)
Number of subjects: 35
Study 4611579 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone (300 mg daily)
Number of subjects: 35
Study 30635055 — intervention group
Group type: EXPERIMENTAL
Intervention: silybin-phosphatidylcholine complex (45 mg)
Number of subjects: 23
Study 30635055 — intervention group
Group type: COMPARATOR
Intervention: conventional silymarin tablets (70 mg)
Number of subjects: 23
Study 28411139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinidine (HQ)
Number of subjects: 50
Study 28411139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25748580 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 123
Study 25748580 — intervention group
Group type: COMPARATOR
Intervention: Tai chi chih (TCC)
Number of subjects: 123
Study 23582482 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 512
Study 23582482 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 512
Study 21552061 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 201
Study 21552061 — intervention group
Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 201
Study 18823212 — intervention group
Group type: EXPERIMENTAL
Intervention: Aural presentation of nonwords with unattested onsets (e.g., bnif, bdif, lbif)
Number of subjects: 0
Study 18823212 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presentation of nonwords with unattested onsets (e.g., bnif, bdif, lbif)
Number of subjects: 0
Study 16284796 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin prophylaxis (somatostatin(+))
Number of subjects: 23
Study 16284796 — intervention group
Group type: COMPARATOR
Intervention: No somatostatin prophylaxis (somatostatin(-))
Number of subjects: 23
Study 16284796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 16284796 — intervention group
Group type: EXPERIMENTAL
Intervention: PPPD surgery
Number of subjects: 23
Study 11854938 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized teaching program during hospitalization, followed by 12 weeks of supportive care via telephone or mail
Number of subjects: 45
Study 11854938 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized teaching program
Number of subjects: 45
Study 11854938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no individualized teaching program)
Number of subjects: 45
Study 11854938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 10673994 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0
Study 10673994 — intervention group
Group type: COMPARATOR
Intervention: Infusional 5-FU therapy (B1, B2, B3 regimens)
Number of subjects: 0
Study 8578185 — intervention group
Group type: EXPERIMENTAL
Intervention: Perendoscopic hemostasis
Number of subjects: 42
Study 8578185 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole infusion
Number of subjects: 42
Study 2349923 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms copper sulfate.kg body wt‐1.d‐1
Number of subjects: 14
Study 2349923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 101071 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose with essential amino acids (21 g/day)
Number of subjects: 6
Study 101071 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose with essential and nonessential amino acids (21 g/day each)
Number of subjects: 6
Study 101071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic glucose alone
Number of subjects: 6
Study 101071 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 6
Study 29324595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinic therapy (4-8 mg daily)
Number of subjects: 645
Study 29324595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 645
Study 27402817 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of atorvastatin
Number of subjects: 0
Study 27402817 — intervention group
Group type: COMPARATOR
Intervention: Switch from lopinavir/ritonavir to atazanavir/ritonavir
Number of subjects: 0
Study 24090619 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence (AD) alone
Number of subjects: 0
Study 24090619 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring alcohol dependence and PTSD
Number of subjects: 0
Study 24090619 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: HSA‐GnRH with FCA
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: DD+MO
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: DD+FIA
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: OA‐GnRH
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: KL‐GnRH
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: HSA‐GnRH
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-booster immunizations against GnRH conjugated to OA
Number of subjects: 156
Study 22147471 — intervention group
Group type: COMPARATOR
Intervention: Control (immunized against OA)
Number of subjects: 156
Study 22147471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-booster immunizations against GnRH conjugated to OA
Number of subjects: 156
Study 20688622 — intervention group
Group type: COMPARATOR
Intervention: L-thyroxine (L-T4)
Number of subjects: 36
Study 20688622 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) + L-triiodothyronine (L-T3)
Number of subjects: 36
Study 18287255 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. once every 2 weeks
Number of subjects: 324
Study 18287255 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa once weekly
Number of subjects: 324
Study 15702319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lowering of intraocular pressure (IOP)
Number of subjects: 0
Study 15702319 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 0
Study 15190655 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary Medicine (CM)
Number of subjects: 43
Study 15190655 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 43
Study 11045391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 11
Study 11045391 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine/Felodipine
Number of subjects: 11
Study 9367398 — intervention group
Group type: EXPERIMENTAL
Intervention: nhuIL-2
Number of subjects: 10
Study 9367398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9367398 — intervention group
Group type: COMPARATOR
Intervention: IVIG infusions during placebo phase
Number of subjects: 10
Study 9367398 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG infusions during nhuIL-2 treatment phase
Number of subjects: 10
Study 1487553 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthroid (600 micrograms)
Number of subjects: 30
Study 1487553 — intervention group
Group type: COMPARATOR
Intervention: Levoxine (600 micrograms)
Number of subjects: 30
Study 3895987 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 62
Study 3895987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31120574 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMDMSCs
Number of subjects: 8
Study 31120574 — intervention group
Group type: COMPARATOR
Intervention: Pooled-allogeneic BMDMSCs
Number of subjects: 8
Study 29436333 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing workshops for 10 weeks
Number of subjects: 134
Study 29436333 — intervention group
Group type: COMPARATOR
Intervention: Group play workshops for 10 weeks
Number of subjects: 134
Study 29436333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 26538428 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (PGx)
Number of subjects: 179
Study 26538428 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 179
Study 24704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking only
Number of subjects: 0
Study 24704737 — intervention group
Group type: COMPARATOR
Intervention: Verbal debrief only
Number of subjects: 0
Study 24704737 — intervention group
Group type: COMPARATOR
Intervention: Combined verbal debrief and eye tracking
Number of subjects: 0
Study 22685047 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g dark chocolate daily for 7 weeks
Number of subjects: 194
Study 22685047 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=70)
Number of subjects: 194
Study 20194880 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple stenting strategy (n=250), main vessel stented with optional kissing balloon dilatation/T-stent.
Number of subjects: 500
Study 20194880 — intervention group
Group type: COMPARATOR
Intervention: Complex stenting strategy (n=250), both vessels systematically stented with mandatory kissing balloon dilatation.
Number of subjects: 500
Study 20194880 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple stenting strategy (n=250).
Number of subjects: 500
Study 20194880 — intervention group
Group type: COMPARATOR
Intervention: Complex stenting strategy (n=250).
Number of subjects: 500
Study 17875243 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-melatonin (Circadin* 2 mg), one tablet per day at 2 hours before bedtime
Number of subjects: 354
Study 17875243 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-melatonin (Circadin* 2 mg)
Number of subjects: 354
Study 17875243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 15937634 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+WLoss (n=16)
Number of subjects: 36
Study 15937634 — intervention group
Group type: COMPARATOR
Intervention: WLoss (n=13)
Number of subjects: 36
Study 15937634 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+WLoss (n=14)
Number of subjects: 36
Study 15937634 — intervention group
Group type: COMPARATOR
Intervention: WLoss (n=12)
Number of subjects: 36
Study 12090325 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day) and azathioprine (100 mg/day) for four months
Number of subjects: 43
Study 12090325 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 43
Study 10319774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil/nitrous oxide anesthesia with bispectral index monitoring
Number of subjects: 274
Study 10319774 — intervention group
Group type: COMPARATOR
Intervention: Propofol/alfentanil/nitrous oxide anesthesia without bispectral index monitoring
Number of subjects: 274
Study 8969780 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient hyperemic response test (carotid artery compression)
Number of subjects: 11
Study 8969780 — intervention group
Group type: COMPARATOR
Intervention: Leg‐cuff test
Number of subjects: 11
Study 1370924 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg/min)
Number of subjects: 12
Study 1370924 — intervention group
Group type: COMPARATOR
Intervention: t‐PA (60 mg in the first hour and a maintenance infusion of 13.3 mg/hr for 3 hours)
Number of subjects: 12
Study 6376145 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glipizide (meal + glipizide)
Number of subjects: 10
Study 6376145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (meal alone)
Number of subjects: 10
Study 30616537 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored counselling for an active life (one face-to-face session, four phone calls, and supportive written material)
Number of subjects: 200
Study 30616537 — intervention group
Group type: COMPARATOR
Intervention: Written general health information only
Number of subjects: 200
Study 29528963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month healthy lifestyle intervention (telephone-based coaching service)
Number of subjects: 160
Study 29528963 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 27620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical glove (SG) compression therapy on the dominant hand
Number of subjects: 42
Study 27620884 — intervention group
Group type: COMPARATOR
Intervention: Control hand (non-dominant hand without SGs)
Number of subjects: 42
Study 27620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical glove (SG) compression therapy
Number of subjects: 42
Study 24146180 — intervention group
Group type: EXPERIMENTAL
Intervention: Open nostril
Number of subjects: 32
Study 24146180 — intervention group
Group type: COMPARATOR
Intervention: Nostril occlusion
Number of subjects: 32
Study 22241317 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 63
Study 22241317 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 63
Study 19544389 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for determining cup orientation in THA using a fully automated registration procedure.
Number of subjects: 407
Study 16420199 — intervention group
Group type: EXPERIMENTAL
Intervention: Uppermost quartile of weight
Number of subjects: 7523
Study 16420199 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of weight gain since age 25
Number of subjects: 7523